Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis
Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect that largely remains an unresolved clinical issue, leading to long-term morbidity. This meta-analysis aimed to evaluate the efficacy and safety of Ganglioside-monosialic acid (GM1) in preventing CIPN...
Guardado en:
Autores principales: | Shaoyong Wu, Xiaohui Bai, Caixia Guo, Zhimei Huang, Handong Ouyang, Jingxiu Huang, Weian Zeng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/78eb99049935487688a6019090bb297a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Anti-ganglioside Antibodies in Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay
por: Jiting Zhu, et al.
Publicado: (2021) -
GM3 Ganglioside Linked to Neurofibrillary Pathology in a Transgenic Rat Model for Tauopathy
por: Dominika Olešová, et al.
Publicado: (2021) -
The structure of gangliosides hides a code for determining neuronal functions
por: Giulia Lunghi, et al.
Publicado: (2021) -
Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson’s Disease?
por: Samar K. Alselehdar, et al.
Publicado: (2021) -
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
por: Nicolas Kerckhove, et al.
Publicado: (2021)